Cargando…
THU298 Effect Of SGLT2 Inhibition On Metabolic, Cardiac And Renal Outcomes In Heart Transplant Recipients (EMPA-HTx study): Protocol And Study Design
Disclosure: L.M. Raven: None. C.A. Muir: None. C. Kessler Iglesias: None. E. Kotlyar: None. K. Muthiah: None. N.K. Bart: Advisory Board Member; Self; Bristol-Myers Squibb. Grant Recipient; Self; Pfizer, Inc. Speaker; Self; Pfizer, Inc. P.S. Macdonald: Speaker; Self; Boehringer Ingelheim, AstraZeneca...
Autores principales: | Raven, Lisa M, Muir, Christopher A, Kessler Iglesias, Cassia, Kotlyar, Eugene, Muthiah, Kavitha, Bart, Nicole K, Macdonald, Peter S, Hayward, Christopher S, Jabbour, Andrew, Greenfield, Jerry R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10555754/ http://dx.doi.org/10.1210/jendso/bvad114.733 |
Ejemplares similares
-
Sodium glucose co-transporter 2 inhibition with empagliflozin on metabolic, cardiac and renal outcomes in recent cardiac transplant recipients (EMPA-HTx): protocol for a randomised controlled trial
por: Raven, Lisa Mary, et al.
Publicado: (2023) -
THU387 Euglycemic Diabetic Ketoacidosis And SGLT-2 Inhibitor Use
por: Abrahimi, Nora, et al.
Publicado: (2023) -
THU360 Hyperglycemic DKA In Patient On Monotherapy With SGLT-2 Inhibitor
por: Ahmed, Samihah, et al.
Publicado: (2023) -
THU389 Euglycemic Diabetic Ketoacidosis With Prolonged Ketosis Due To SGLT-2 Inhibitor
por: Viera Feliciano, Natalia, et al.
Publicado: (2023) -
THU247 Characterizing Inpatient Cases Of DKA Precipitated By SGLT2 Inhibitor Use
por: Aslamy, Arianne, et al.
Publicado: (2023)